Creative Planning Acquires 4,937 Shares of Glaukos Co. (NYSE:GKOS)

Creative Planning boosted its holdings in shares of Glaukos Co. (NYSE:GKOS) by 64.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,643 shares of the medical instruments supplier’s stock after buying an additional 4,937 shares during the quarter. Creative Planning’s holdings in Glaukos were worth $1,647,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its stake in shares of Glaukos by 127.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 166,054 shares of the medical instruments supplier’s stock worth $15,657,000 after acquiring an additional 93,076 shares during the last quarter. Texas Permanent School Fund Corp raised its holdings in Glaukos by 1.5% in the 1st quarter. Texas Permanent School Fund Corp now owns 42,709 shares of the medical instruments supplier’s stock worth $4,027,000 after purchasing an additional 622 shares during the period. Duality Advisers LP purchased a new position in Glaukos during the first quarter valued at $3,476,000. Oppenheimer & Co. Inc. bought a new stake in Glaukos during the first quarter valued at about $217,000. Finally, Lisanti Capital Growth LLC bought a new stake in Glaukos during the first quarter valued at about $3,969,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on GKOS shares. Piper Sandler set a $140.00 price objective on Glaukos in a research report on Thursday, October 17th. Stifel Nicolaus lifted their price target on shares of Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. StockNews.com upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Morgan Stanley raised their price objective on shares of Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Finally, Needham & Company LLC lifted their target price on shares of Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $130.45.

Insider Activity

In related news, Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the sale, the director now owns 32,336 shares in the company, valued at approximately $4,225,345.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, COO Joseph E. Gilliam sold 5,000 shares of the stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total value of $646,800.00. Following the completion of the transaction, the chief operating officer now owns 102,169 shares of the company’s stock, valued at approximately $13,216,581.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,250 shares of company stock worth $4,825,873. 6.40% of the stock is currently owned by insiders.

Glaukos Stock Up 2.7 %

GKOS opened at $137.75 on Wednesday. Glaukos Co. has a 52 week low of $59.22 and a 52 week high of $137.81. The company has a quick ratio of 4.67, a current ratio of 5.48 and a debt-to-equity ratio of 0.19. The firm has a 50-day simple moving average of $129.22 and a two-hundred day simple moving average of $118.66. The company has a market capitalization of $6.94 billion, a PE ratio of -47.83 and a beta of 1.02.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, meeting the consensus estimate of ($0.52). The business had revenue of $95.70 million during the quarter, compared to analysts’ expectations of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.55) EPS. Analysts forecast that Glaukos Co. will post -2.16 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.